GOG3104
Brief description of study
This is a randomized, open-label, global Phase 3 study designed to assess the effect of sacituzumab govitecan (SG) compared with TPC (doxorubicin or paclitaxel) in participants with recurrent/persistent endometrial cancer who have received prior treatment with platinum-based chemotherapy and anti-programmed cell death protein 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) therapy. Eligible participants will be randomized in a 1:1 ratio to receive either SG or TPC.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
